ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $264,432 | -24.3% | 7,419 | -2.1% | 0.00% | -100.0% |
| Q2 2023 | $349,298 | +55.9% | 7,578 | +35.4% | 0.00% | – |
| Q1 2023 | $224,063 | -2.2% | 5,596 | +14.0% | 0.00% | – |
| Q4 2022 | $229,000 | +41.4% | 4,908 | +26.2% | 0.00% | – |
| Q3 2022 | $162,000 | -5.3% | 3,890 | +34.6% | 0.00% | – |
| Q2 2022 | $171,000 | -13.6% | 2,890 | +2.7% | 0.00% | – |
| Q1 2022 | $198,000 | -16.1% | 2,815 | -0.5% | 0.00% | – |
| Q4 2021 | $236,000 | +61.6% | 2,830 | +75.6% | 0.00% | – |
| Q3 2021 | $146,000 | +19.7% | 1,612 | +26.6% | 0.00% | – |
| Q2 2021 | $122,000 | -60.1% | 1,273 | -52.4% | 0.00% | -100.0% |
| Q1 2021 | $306,000 | +20.9% | 2,674 | +46.8% | 0.00% | 0.0% |
| Q4 2020 | $253,000 | +97.7% | 1,822 | +15.8% | 0.00% | – |
| Q3 2020 | $128,000 | +42.2% | 1,574 | +36.2% | 0.00% | – |
| Q2 2020 | $90,000 | +109.3% | 1,156 | +20.5% | 0.00% | – |
| Q1 2020 | $43,000 | – | 959 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |